温州市鹿城区预防接种室消毒与污染状况调查

为了解我区预防接种室局部消毒的质量和微环境污染状况,对我区街道和村的预防注射室消毒及污染情况进行了调查。其中酒精消毒液浓度、染菌量和空气、操作台面、手染菌量合格率分别为37．5％、36．6％、38．1％、68．3％、43．2％．街道卫生院的酒精消毒液浓度、台面和手染菌量合格率高于村卫生室;酒精和空气染菌量街道卫生院和村卫生室两级单位无明显差别。一次性注射器无菌试验合格率为100％．调查结果表明,我区预防注射室的消毒质量不高,环境污染比较严重。本文分析了原因,提出了改进建议。     

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer

Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) may derive significant clinical benefit from targeted therapies against this driver mutation, but progression is virtually inevitable. Alectinib is a next-generation ALK inhibitor that provides a novel treatment option for this group of patients.

Areas covered: In this review, we summarize the overall safety and tolerability of alectinib. Specifically, we cover cardiovascular, gastrointestinal, hepatic, musculoskeletal, and respiratory adverse events. The safety profile of alectinib is also described in special populations and in comparison with other ALK inhibitors.

Expert opinion: Alectinib is a well-tolerated tyrosine kinase inhibitor and should be considered for patients with ALK-rearranged NSCLC. The question then arises as to how to choose a next-generation ALK inhibitor in the second-line setting. Understanding acquired resistant mechanisms has become essential. Whether or not to use alectinib in the first-line setting is extremely controversial, but we anticipate its approval for this indication and availability in more countries in the near future.